Indaptus Therapeutics Fails Nasdaq Listing Standards
Ticker: INDP · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, compliance
TL;DR
Indaptus Therapeutics is getting kicked off Nasdaq for not meeting bid price rules.
AI Summary
Indaptus Therapeutics, Inc. filed an 8-K on January 31, 2025, to report its failure to meet the continued listing standards of the Nasdaq Capital Market. The company was notified by Nasdaq on January 29, 2025, that it was not in compliance with the minimum bid price requirement, and it has not yet regained compliance. Indaptus Therapeutics, Inc. was formerly known as Intec Parent Inc. until April 14, 2021.
Why It Matters
Failure to meet listing standards can lead to delisting from a major exchange, potentially reducing liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company has failed to meet Nasdaq's continued listing standards, increasing the risk of delisting.
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Exchange where listing standards were not met
- January 31, 2025 (date) — Filing date of the 8-K
- January 29, 2025 (date) — Date Nasdaq notified the company
- Intec Parent Inc. (company) — Former company name
- April 14, 2021 (date) — Date of former company name change
FAQ
What specific Nasdaq listing rule did Indaptus Therapeutics fail to meet?
Indaptus Therapeutics failed to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
When was Indaptus Therapeutics notified of its non-compliance?
The company was notified by Nasdaq on January 29, 2025.
Has Indaptus Therapeutics regained compliance with Nasdaq's listing standards?
As of the filing date of January 31, 2025, the company has not yet regained compliance.
What was Indaptus Therapeutics' former name?
Indaptus Therapeutics, Inc. was formerly known as Intec Parent Inc.
What is the company's principal executive office address?
The company's principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY 10019.
Filing Stats: 772 words · 3 min read · ~3 pages · Grade level 15 · Accepted 2025-01-31 16:15:09
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INDP Nasdaq Capital Mark
- $1.00 — ties to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-25-004428.txt ( ) — 203KB
- indp-20250131.xsd (EX-101.SCH) — 3KB
- indp-20250131_lab.xml (EX-101.LAB) — 33KB
- indp-20250131_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 31, 2025 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer